<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761341</url>
  </required_header>
  <id_info>
    <org_study_id>FLOS Study</org_study_id>
    <nct_id>NCT04761341</nct_id>
  </id_info>
  <brief_title>FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment</brief_title>
  <acronym>FLOS</acronym>
  <official_title>FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of lutein supplementation on macular pigment density using FLIO&#xD;
      and MPOD measurements in patients with age-related macular degeneration and healthy subjects&#xD;
      over a course of 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The human macula is a small area of the retina responsible for central vision. The yellow&#xD;
      macular pigment contains three carotenoids, lutein ((3R,3'R,6'R)-lutein), zeaxanthin&#xD;
      ((3R,3'R)-zeaxanthin), and meso-zeaxanthin ((3R,3'S;meso)-zeaxanthin). The human body is&#xD;
      unable to synthesize lutein and zeaxanthin, thus needs to be obtained from dietary sources&#xD;
      such as green leafy vegetables and supplements. The function of the macular pigment is to act&#xD;
      as a filter by absorbing blue light that may attenuate photochemical damage of the retina.&#xD;
      Furthermore, it protects against light induced oxidative damage by functioning as an&#xD;
      antioxidant; scavenging free radicals. A growing body of evidence has established a link&#xD;
      between the concentrations of the macular pigment carotenoids, the macular pigment optical&#xD;
      density (MPOD) levels, visual performance and the risk of macular degeneration.&#xD;
&#xD;
      The ability of the macular pigment to absorb or filter blue light can be measured as macular&#xD;
      pigment optical density (MPOD), which is directly related to the quantity of lutein and&#xD;
      zeaxanthin in the macula. Furthermore, preliminary data showed that macular pigment can be&#xD;
      evaluated using Fluorescence lifetime imaging ophthalmoscopy (FLIO). In a previous study the&#xD;
      investigators have shown that FLIO provides contrast for macular pigment in patients with AMD&#xD;
      and healthy subjects.&#xD;
&#xD;
      The purpose of this study is to investigate the effects of oral lutein supplementation on&#xD;
      macular pigment density using FLIO and MPOD measurements in healthy subjects and patients&#xD;
      with age-related macular degeneration (AMD) over a course of 6 months. Furthermore, the&#xD;
      investigators will assess whether compositional and functional alterations of the gut&#xD;
      metagenome may be related to age-related macular degeneration, and the effects of lutein&#xD;
      supplementation on the gut. In addition, to blood samples, stool samples will be analysed&#xD;
      accordingly to the currently running study on &quot;The role of the gut metagenome on the&#xD;
      development of ophthalmic diseases&quot; ClinicalTrials.gov Identifier: NCT02438111. Faecal&#xD;
      analyses will provide insight to how oral lutein supplementation effects the gut microbiota&#xD;
      and how it is influenced by serum lutein Levels.&#xD;
&#xD;
      Objective is to investigate the effects of lutein supplementation on macular pigment density&#xD;
      using FLIO and MPOD measurements in patients with age-related macular degeneration and&#xD;
      healthy subjects over a course of 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MPOD (macular pigment optical Density)</measure>
    <time_frame>6 Months</time_frame>
    <description>Method to detect changes in macular pigment optic Density using dual wavelength autofluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO)</measure>
    <time_frame>6 Months</time_frame>
    <description>Retinal Autofluorescence lifetimes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular pigment screener (MPS) II</measure>
    <time_frame>6 Months</time_frame>
    <description>Screening Method to detect changes in macular pigment optic Density using heterochromatic flicker photometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>6 Months</time_frame>
    <description>Using Pelli-Robson charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 Months</time_frame>
    <description>Visual acuity using ETDRS charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lutein concentration</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Analysis namely taxonomic and functional characterization of gut microbiota</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NUTROF TOTAL</intervention_name>
    <description>1 per day over a course of 3 months</description>
    <arm_group_label>AMD</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be willing to give written informed consent&#xD;
&#xD;
          -  Probands 18 years of age or greater&#xD;
&#xD;
          -  Both eyes will be assessed in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opacities of ocular media excluding detailed observation of the retina&#xD;
&#xD;
          -  Gastrointestinal diseases that could cause disturbance of dietary absorption&#xD;
&#xD;
          -  History of lutein supplementation&#xD;
&#xD;
          -  Allergy to lutein and zeaxanthin&#xD;
&#xD;
          -  Missing compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Zinkernagel, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

